Could carbon monoxide help Parkinson's? new trial launches
NCT ID NCT07005180
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tests an experimental drug called HBI-002, a low-dose carbon monoxide liquid taken by mouth daily for 14 days. It aims to see if the drug is safe and tolerable in 36 adults aged 40-80 with Parkinson's disease. Participants are randomly assigned to receive the drug or a placebo, and neither they nor the doctors know which they get.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Quest Research Institute
RECRUITINGFarmington Hills, Michigan, 48334, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.